Results 51 to 60 of about 624 (180)
[Therapeutic efficacy of mildronate in pulmonary diseases].
Likars'ka sprava, 2006 Immuno-corrective action of the medication has been proved by analyzing Mildronate administration in 64 patients with bronchial asthma and secondary immunodeficiency. Stimulation of sell component and inhibition of humoral component of the immunity system, improvement of central hemodynamics and normalization of the hemopoiesis system to some extent ...
V P, Mkrtchian, V A, Orlov
openaire +1 more source
Cardioprotective measures in patients with cardiovascular risk factors and polymorbidity
Лечащий Врач, 2022 4th international educational forum «Russian Days of the Heart» took place in St. Petersburg, 22 June 2022. Its program included a satellite symposium «Actual cardioneurology: cardiovascular risk factors and polymorbidity» that was held with the support ...
article Editorial
doaj
MILDRONATE POTENTIAL IN PATIENTS WITH CARDIOVASCULAR DISEASE
Российский кардиологический журнал, 2010 .
V. P. Mikhin, F. E. Khlebodarov
openaire +1 more source
COMPARING MOLECULAR EFFECTS OF VARIOUS CYTOPROTECTORS IN COMPLEX THERAPY OF CORONARY HEART DISEASE
Российский кардиологический журнал, 2009 The molecular effects of trimetazidine and mildronate were investigated in patients with stable effort angina, Functional Class (FC) I-III. The comparison criteria included blood activity and concentrations of the main products of free-radical oxidation ...
E. A. Kartashova
doaj
[Mildronate in geriatric patients with cardiac failure].
Terapevticheskii arkhiv, 2006 To study efficacy of mildronate in the treatment of elderly patients with cardiac failure (CF).A total of 91 patients with chronic CF (NYHA FC I-III) entered the study. The study group of 63 patients received standard therapy for a month and mildronate in a dose 750 mg/day. The control group of 28 patients was treated conventionally.
I, Kalvinsh +5 more
openaire +1 more source
Российский кардиологический журнал, 2006 The results of myocardial cytoprotection with mildronate and trimethazidine (Preductal MB) in stable angina patients with left ventricular (LV) myocardial dysfunction, including hibernation, are presented.
I. G. Gordeev +5 more
doaj
CYTOPROTECTOR ROLE IN THE MANAGEMENT OF ARTERIAL HYPERTENSION TREATED WITH ENALAPRIL
Российский кардиологический журнал, 2009 The study investigated the effects of cardiac cytoprotectors – mildronate and trimetazidine, combined with ACE therapy, on lipid peroxidation product levels, endothelial function, circadian blood pressure (BP) profile, left ventricular myocardium, and ...
F. E. Khebodarov, V. P. Mikhin
doaj
Кардиоцитопротекторы — новое направление клинической кардиологии
Архивъ внутренней медицины, 2011 Treatment and secondary prevention of cardiovascular diseases, which are based on coronary heart disease and hypertension, remains one of the most urgent problems of modern cardiology.
В. П. Мухин
doaj +1 more source
Российский кардиологический журнал, 2009 The study compared the effects of cardiocytoprotectors (mildronate, trimetazidine) on endothelial function, physical stress tolerability, and circadian blood pressure (BP) profile in patients with arterial hypertension (AH; n=60) and stable angina (n=82),
F. E. Khlebodarov +2 more
doaj
Архивъ внутренней медицины, 2015 A randomized study of the state of stiffness parameters arteries wall (CAVI — cardio-ankle vascular index), AI (augmentation index) PEP (duration of the voltage of the left ventricle) using «VaSera-1000» («Fukuda Denshi», Japan) in primary hypertension ...
V. P. Mikhin +3 more
doaj +1 more source